Systemic sclerosis endothelial cells recruit and activate dermal fibroblasts by induction of a connective tissue growth factor (CCN2)/transforming growth factor β-dependent mesenchymal-to-mesenchymal transition.

OBJECTIVE Clinical evidence suggests that the vascular abnormalities of systemic sclerosis (SSc) precede the onset of fibrosis, but molecular cues accounting for a possible vascular connection of SSc fibrosis have been elusive, although they have been searched for intensively. Since we had previously shown that connective tissue growth factor (CCN2), endowed with fibroblast-oriented activities, was overexpressed by endothelial cells (ECs) from SSc patients, we undertook this study to investigate its role and mechanisms in fibroblast activation. METHODS Normal fibroblasts were challenged with conditioned medium of normal microvascular ECs (MVECs) and MVECs obtained from SSc patients with the diffuse form of the disease. Fibroblast invasion was studied using the Boyden chamber Matrigel assay. Fibroblast activation was evaluated by Western blotting and immunofluorescence of α-smooth muscle actin (α-SMA), vimentin, and type I collagen. Matrix metalloproteinase (MMP) production was evaluated by zymography and reverse transcription-polymerase chain reaction. Signal transduction and activation of the small GTPases RhoA and Rac1 were studied by Western blotting. Inhibition of SSc MVEC conditioned medium-dependent fibroblast activation was obtained by anti-CCN2 antibodies and the transforming growth factor β (TGFβ) antagonist peptide p17. RESULTS SSc MVEC CCN2 stimulated fibroblast activation and invasion. Such activities depended on CCN2-induced overexpression of TGFβ and its type I, II, and III receptors combined with overproduction of MMP-2 and MMP-9 gelatinases. All of these effects were reversed by the TGFβ antagonist peptide p17. Motility increase required Rac1 activation and RhoA inhibition and was inhibited by an MMP inhibitor. These features connoted a mesenchymal style of cell invasion. Since fibroblast activation also fostered overexpression of α-SMA, vimentin, and type I collagen, the CCN2-dependent increase in fibroblast activities recapitulated the characteristics of a mesenchymal-to-mesenchymal transition. CONCLUSION SSc MVECs recruit and activate dermal fibroblasts by induction of a CCN2/TGFβ-dependent mesenchymal-to-mesenchymal transition.

[1]  L. Magnelli,et al.  Endothelial progenitor cell-dependent angiogenesis requires localization of the full-length form of uPAR in caveolae. , 2011, Blood.

[2]  A. Leask.  Possible strategies for anti-fibrotic drug intervention in scleroderma , 2011, Journal of Cell Communication and Signaling.

[3]  Michael L Whitfield,et al.  The pathogenesis of systemic sclerosis. , 2011, Annual review of pathology.

[4]  S. Bombardieri,et al.  Modulation of the angiogenic phenotype of normal and systemic sclerosis endothelial cells by gain-loss of function of pentraxin 3 and matrix metalloproteinase 12. , 2010, Arthritis and rheumatism.

[5]  M. Trojanowska.  Noncanonical transforming growth factor β signaling in scleroderma fibrosis , 2009, Current opinion in rheumatology.

[6]  M. T. Grande,et al.  Fibroblast activation and myofibroblast generation in obstructive nephropathy , 2009, Nature Reviews Nephrology.

[7]  P. Chiarugi,et al.  EphA2 reexpression prompts invasion of melanoma cells shifting from mesenchymal to amoeboid-like motility style. , 2009, Cancer research.

[8]  A. Albini,et al.  TGFbeta1 antagonistic peptides inhibit TGFbeta1-dependent angiogenesis. , 2009, Biochemical pharmacology.

[9]  D. Abraham,et al.  Connective tissue growth factor: growth factor, matricellular organizer, fibrotic biomarker or molecular target for anti-fibrotic therapy in SSc? , 2008, Rheumatology.

[10]  D. Abraham,et al.  Regulation and function of connective tissue growth factor/CCN2 in tissue repair, scarring and fibrosis. , 2008, Cytokine & growth factor reviews.

[11]  J. Prieto,et al.  Identification of peptide inhibitors of transforming growth factor beta 1 using a phage-displayed peptide library. , 2007, Cytokine.

[12]  D. Nosi,et al.  Domain 1 of the urokinase-type plasminogen activator receptor is required for its morphologic and functional, beta2 integrin-mediated connection with actin cytoskeleton in human microvascular endothelial cells: failure of association in systemic sclerosis endothelial cells. , 2006, Arthritis and rheumatism.

[13]  S. Bombardieri,et al.  Systemic sclerosis fibroblasts inhibit in vitro angiogenesis by MMP‐12‐dependent cleavage of the endothelial cell urokinase receptor , 2006, The Journal of pathology.

[14]  H. Steinbrenner,et al.  Enhancement of tumor invasion depends on transdifferentiation of skin fibroblasts mediated by reactive oxygen species , 2006, Journal of Cell Science.

[15]  D. Abraham,et al.  Overview of pathogenesis of systemic sclerosis. , 2006, Rheumatology.

[16]  B. Giusti,et al.  The antiangiogenic tissue kallikrein pattern of endothelial cells in systemic sclerosis. , 2005, Arthritis and rheumatism.

[17]  Jiri Zavadil,et al.  TGF-β and epithelial-to-mesenchymal transitions , 2005, Oncogene.

[18]  D. Yamazaki,et al.  Regulation of cancer cell motility through actin reorganization , 2005, Cancer science.

[19]  M. Cinelli,et al.  Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis. , 2004, Arthritis and rheumatism.

[20]  Andrew Leask,et al.  TGF‐β signaling and the fibrotic response , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[21]  P. Friedl.  Prespecification and plasticity: shifting mechanisms of cell migration. , 2004, Current opinion in cell biology.

[22]  D. Abraham,et al.  The role of connective tissue growth factor, a multifunctional matricellular protein, in fibroblast biology. , 2003, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[23]  P. Friedl,et al.  Tumour-cell invasion and migration: diversity and escape mechanisms , 2003, Nature Reviews Cancer.

[24]  P. Greenwel,et al.  A synthetic peptide from transforming growth factor beta type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury. , 2003, Cytokine.

[25]  A. Strongin,et al.  Compensation mechanism in tumor cell migration , 2003, The Journal of cell biology.

[26]  E. Robertis,et al.  Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-β , 2002, Nature Cell Biology.

[27]  M. Takigawa,et al.  Role and interaction of connective tissue growth factor with transforming growth factor‐β in persistent fibrosis: A mouse fibrosis model , 1999, Journal of cellular physiology.

[28]  T. Matsumura,et al.  Connective tissue growth factor induces the proliferation, migration, and tube formation of vascular endothelial cells in vitro, and angiogenesis in vivo. , 1999, Journal of biochemistry.

[29]  S. Milani,et al.  Functions of the fibrinolytic system in human ito cells and its control by basic fibroblast and platelet‐derived growth factor , 1999, Hepatology.

[30]  E. Leroy.  SYSTEMIC SCLEROSIS : A Vascular Perspective , 1996 .

[31]  A. Masi.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.

[32]  James F. Fries,et al.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. , 1980, Arthritis and rheumatism.

[33]  Ying E Zhang,et al.  Non-Smad pathways in TGF-β signaling , 2009, Cell Research.

[34]  X. Chevalier,et al.  Nerve root pain secondary to posterior articular cysts: a report of 6 cases and review of the literature. , 1992, Clinical and experimental rheumatology.